Importance: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Objective: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant. Design, Setting, and Participants: In this randomized phase 3 clinical trial, patients were enrolled November 2015 to July 2019 (data cutoff, July 17, 2019). Investigators at 47 centers in 13 countries enrolled children older than 28 days and younger than 18 years with high-risk first-relapse B-ALL in morphologic complete remission (M1 marrow, <5% blasts) or with M2 marrow (blasts ≥5% and <25%) at randomization. Intervention: Patients were randomized to receive 1 cycle of blinatumomab (n = 54; 15 μg/m2/d for 4 weeks, continuous intravenous infusion) or chemotherapy (n = 54) for the third consolidation. Main Outcomes and Measures: The primary end point was event-free survival (events: relapse, death, second malignancy, or failure to achieve complete remission). The key secondary efficacy end point was overall survival. Other secondary end points included minimal residual disease remission and incidence of adverse events. Results: A total of 108 patients were randomized (median age, 5.0 years [interquartile range {IQR}, 4.0-10.5]; 51.9% girls; 97.2% M1 marrow) and all patients were included in the analysis. Enrollment was terminated early for benefit of blinatumomab in accordance with a prespecified stopping rule. After a median of 22.4 months of follow-up (IQR, 8.1-34.2), the incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57% (log-rank P < .001; hazard ratio [HR], 0.33 [95% CI, 0.18-0.61]). Deaths occurred in 8 patients (14.8%) in the blinatumomab group and 16 (29.6%) in the consolidation chemotherapy group. The overall survival HR was 0.43 (95% CI, 0.18-1.01). Minimal residual disease remission was observed in more patients in the blinatumomab vs consolidation chemotherapy group (90% [44/49] vs 54% [26/48]; difference, 35.6% [95% CI, 15.6%-52.5%]). No fatal adverse events were reported. In the blinatumomab vs consolidation chemotherapy group, the incidence of serious adverse events was 24.1% vs 43.1%, respectively, and the incidence of adverse events greater than or equal to grade 3 was 57.4% vs 82.4%. Adverse events leading to treatment discontinuation were reported in 2 patients in the blinatumomab group. Conclusions and Relevance: Among children with high-risk first-relapse B-ALL, treatment with 1 cycle of blinatumomab compared with standard intensive multidrug chemotherapy before allogeneic hematopoietic stem cell transplant resulted in an improved event-free survival at a median of 22.4 months of follow-up. Trial Registration: ClinicalTrials.gov Identifier: NCT02393859.

Amgen Inc Thousand Oaks California

Amgen Ltd Uxbridge United Kingdom

Amgen Research Munich Germany

Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon Naples Italy

Charité Universitätsmedizin Berlin Berlin Germany

Charles University Motol University Hospital Prague Czech Republic

IRCCS Istituto Giannina Gaslini Genova Italy

IRCCS Ospedale Pediatrico Bambino Gesù and Sapienza University of Rome Rome Italy

Jena University Hospital Jena Germany

Medizinische Hochschule Hannover Hannover Germany

Sorbonne Université Hôpital Armand Trousseau AP HP Paris France

St Anna Children's Hospital Vienna Austria

Tata Translational Cancer Research Center Tata Medical Center Kolkata West Bengal India

The University of Manchester Manchester United Kingdom

Universitätsklinikum Frankfurt am Main Frankfurt Germany

Universitätsklinikum Freiburg Freiburg Germany

Universitätsklinikum Schleswig Holstein Kiel Germany

University of Milano Bicocca MBBM Foundation Monza Italy

Westmead Hospital Sydney New South Wales Australia

000      

00000naa a2200000 a 4500

001      

bmc21011440

003      

CZ-PrNML

005      

20210507102902.0

007      

ta

008      

210420s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1001/jama.2021.0987 $2 doi

035    __

$a (PubMed)33651091

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Locatelli, Franco $u IRCCS Ospedale Pediatrico Bambino Gesù and Sapienza University of Rome, Rome, Italy

245    10

$a Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial / $c F. Locatelli, G. Zugmaier, C. Rizzari, JD. Morris, B. Gruhn, T. Klingebiel, R. Parasole, C. Linderkamp, C. Flotho, A. Petit, C. Micalizzi, N. Mergen, A. Mohammad, WN. Kormany, C. Eckert, A. Möricke, M. Sartor, O. Hrusak, C. Peters, V. Saha, L. Vinti, A. von Stackelberg

520    9_

$a Importance: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Objective: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant. Design, Setting, and Participants: In this randomized phase 3 clinical trial, patients were enrolled November 2015 to July 2019 (data cutoff, July 17, 2019). Investigators at 47 centers in 13 countries enrolled children older than 28 days and younger than 18 years with high-risk first-relapse B-ALL in morphologic complete remission (M1 marrow, <5% blasts) or with M2 marrow (blasts ≥5% and <25%) at randomization. Intervention: Patients were randomized to receive 1 cycle of blinatumomab (n = 54; 15 μg/m2/d for 4 weeks, continuous intravenous infusion) or chemotherapy (n = 54) for the third consolidation. Main Outcomes and Measures: The primary end point was event-free survival (events: relapse, death, second malignancy, or failure to achieve complete remission). The key secondary efficacy end point was overall survival. Other secondary end points included minimal residual disease remission and incidence of adverse events. Results: A total of 108 patients were randomized (median age, 5.0 years [interquartile range {IQR}, 4.0-10.5]; 51.9% girls; 97.2% M1 marrow) and all patients were included in the analysis. Enrollment was terminated early for benefit of blinatumomab in accordance with a prespecified stopping rule. After a median of 22.4 months of follow-up (IQR, 8.1-34.2), the incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57% (log-rank P < .001; hazard ratio [HR], 0.33 [95% CI, 0.18-0.61]). Deaths occurred in 8 patients (14.8%) in the blinatumomab group and 16 (29.6%) in the consolidation chemotherapy group. The overall survival HR was 0.43 (95% CI, 0.18-1.01). Minimal residual disease remission was observed in more patients in the blinatumomab vs consolidation chemotherapy group (90% [44/49] vs 54% [26/48]; difference, 35.6% [95% CI, 15.6%-52.5%]). No fatal adverse events were reported. In the blinatumomab vs consolidation chemotherapy group, the incidence of serious adverse events was 24.1% vs 43.1%, respectively, and the incidence of adverse events greater than or equal to grade 3 was 57.4% vs 82.4%. Adverse events leading to treatment discontinuation were reported in 2 patients in the blinatumomab group. Conclusions and Relevance: Among children with high-risk first-relapse B-ALL, treatment with 1 cycle of blinatumomab compared with standard intensive multidrug chemotherapy before allogeneic hematopoietic stem cell transplant resulted in an improved event-free survival at a median of 22.4 months of follow-up. Trial Registration: ClinicalTrials.gov Identifier: NCT02393859.

650    _2

$a mladiství $7 D000293

650    _2

$a protilátky bispecifické $x škodlivé účinky $x terapeutické užití $7 D018033

650    _2

$a antitumorózní látky $x škodlivé účinky $x terapeutické užití $7 D000970

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971

650    _2

$a dítě $7 D002648

650    _2

$a předškolní dítě $7 D002675

650    _2

$a kombinovaná terapie $7 D003131

650    _2

$a chemoterapie konsolidační $x škodlivé účinky $7 D060830

650    _2

$a přežití po terapii bez příznaků nemoci $7 D018572

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    12

$a transplantace hematopoetických kmenových buněk $7 D018380

650    _2

$a lidé $7 D006801

650    12

$a imunoterapie $7 D007167

650    _2

$a kojenec $7 D007223

650    _2

$a Kaplanův-Meierův odhad $7 D053208

650    _2

$a leukemie B-buněčná $x farmakoterapie $x mortalita $7 D015448

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a akutní lymfatická leukemie $x farmakoterapie $x mortalita $x terapie $7 D054198

650    _2

$a recidiva $7 D012008

650    _2

$a rizikové faktory $7 D012307

650    _2

$a míra přežití $7 D015996

655    _2

$a klinické zkoušky, fáze III $7 D017428

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Zugmaier, Gerhard $u Amgen Research (Munich GmbH), Munich, Germany

700    1_

$a Rizzari, Carmelo $u University of Milano-Bicocca, MBBM Foundation, Monza, Italy

700    1_

$a Morris, Joan D $u Amgen Inc, Thousand Oaks, California

700    1_

$a Gruhn, Bernd $u Jena University Hospital, Jena, Germany

700    1_

$a Klingebiel, Thomas $u Universitätsklinikum Frankfurt am Main, Frankfurt, Germany

700    1_

$a Parasole, Rosanna $u Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon, Naples, Italy

700    1_

$a Linderkamp, Christin $u Medizinische Hochschule Hannover, Hannover, Germany

700    1_

$a Flotho, Christian $u Universitätsklinikum Freiburg, Freiburg, Germany

700    1_

$a Petit, Arnaud $u Sorbonne Université, Hôpital Armand Trousseau, AP-HP, Paris, France

700    1_

$a Micalizzi, Concetta $u IRCCS Istituto Giannina Gaslini, Genova, Italy

700    1_

$a Mergen, Noemi $u Amgen Research (Munich GmbH), Munich, Germany

700    1_

$a Mohammad, Abeera $u Amgen Ltd, Uxbridge, United Kingdom

700    1_

$a Kormany, William N $u Amgen Inc, Thousand Oaks, California

700    1_

$a Eckert, Cornelia $u Charité-Universitätsmedizin Berlin, Berlin, Germany

700    1_

$a Möricke, Anja $u Universitätsklinikum Schleswig-Holstein, Kiel, Germany

700    1_

$a Sartor, Mary $u Westmead Hospital, Sydney, New South Wales, Australia

700    1_

$a Hrusak, Ondrej $u Charles University, Motol University Hospital, Prague, Czech Republic

700    1_

$a Peters, Christina $u St Anna Children's Hospital, Vienna, Austria

700    1_

$a Saha, Vaskar $u The University of Manchester, Manchester, United Kingdom $u Tata Translational Cancer Research Center, Tata Medical Center, Kolkata, West Bengal, India

700    1_

$a Vinti, Luciana $u IRCCS Ospedale Pediatrico Bambino Gesù and Sapienza University of Rome, Rome, Italy

700    1_

$a von Stackelberg, Arend $u Charité-Universitätsmedizin Berlin, Berlin, Germany

773    0_

$w MED00002973 $t JAMA $x 1538-3598 $g Roč. 325, č. 9 (2021), s. 843-854

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33651091 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210420 $b ABA008

991    __

$a 20210507102900 $b ABA008

999    __

$a ok $b bmc $g 1649966 $s 1131819

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 325 $c 9 $d 843-854 $e 20210302 $i 1538-3598 $m JAMA (Chicago, Ill.) $n JAMA $x MED00002973

LZP    __

$a Pubmed-20210420